[1] |
LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan.
Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
|
[2] |
SHEN Lu, LIU Cuili, WANG Yi, HAO Mingqiang, WANG Yali, ZHU Huijuan, WU Chen, YANG Yang.
Precision Pharmacovigilance for Cell and Gene Therapy Products
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 633-639.
|
[3] |
LIANG Fanglin, CHEN Lingyuan, HU Danli, WEI Lingyun, WEI Tiemeng, ZHANG Faen, WEI Yana.
Immune-Related Adverse Events of Tislelizumab in 120 Patients with Hepatocellular Carcinoma
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 659-663.
|
[4] |
WANG Jiaqing, WANG Qi, LIU Tongtong, ZHANG Dongjie, CHEN Qi, MEI Shenghui, NING Xiao.
Determination of Linezolid Concentrations in Plasma with HPLC-MS/MS Method
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 377-380.
|
[5] |
LAN Xiaoqian, GUO Wei.
Trough Steady-State Concentration/Dose Ratio and Contributors to Adverse Drug Reactions of Sulpiride
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 420-423.
|
[6] |
CAO Yin, ZHOU Xuan, DAI Biao, DENG Yiyun, YAN Chunyu, SHAN Feng, XIA Qingrong, LIANG Jun.
A UPLC-MS/MS method for determination of human serum trazodone concentration and its clinical individualized medications
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 991-997.
|
[7] |
LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming.
Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications”
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
|
[8] |
LIN Lu, ZHAN Luchuan, LIU Xiaoqi, LIU Ju'e, WANG Laiyou, ZENG Ying, LAI Weihua.
Establish triggers for active monitoring of digoxin adverse events based on the China hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1039-1043.
|
[9] |
ZHANG Caixia, ZHOU Yi, TAN Lu, CHEN Wenming, LIU Yang, YOU Yu.
Pharmaceutical care of pulmonary aspergillus infection secondary to sepsis
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1064-1067.
|
[10] |
ZHANG Qian, YUN Yuan, HE Lian.
Pharmaceutical care of hyperprolactinemia in a patient induced by risperidone
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 936-938.
|
[11] |
WANG Dan, DONG Duo, TIAN Chunhua.
Course of development of pharmocovigilance systems in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 735-740.
|
[12] |
CHENG Yijing, LI Tao, LIU Junting, HUANG Guimin, ZHONG Xuli, LIN Aihua, PAN Shoudong, LI Long, BAI Dongsheng, ZHAN Xiaojun, LIU Zhenjiang, REN Wei, NIE Xiaolu, TAI Jun.
Safety evaluation of haemocoagulase agkistrodon for injection in children based on real world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 787-790.
|
[13] |
XIA Lanfang, LI Keli, WANG Lei, LI Yan, WANG Huaqing.
Impact of comparator selection on signal detection in adverse events following immunization in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 798-804.
|
[14] |
SU Xiaohan, ZENG Jiao, LI Xue, LIU Lixin, HOU Lingmi, LI Jinsui.
Adverse events of abemaciclib in breast cancer patients based on US FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 580-586.
|
[15] |
ZHANG Jian, ZHANG Lingli, LI Xin.
Immune-related adverse events of tirelizumab in 424 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 435-439.
|